Respiratory Diagnostics Market Insights: Size, Share, Growth Analysis & Forecast (2024-2029)

The market report presents a thorough analysis segmented by Product and Service (Instruments & Devices, Assays & Reagents, Software); by Test Type (Mechanical Tests, Osa Diagnostic Tests, Imaging Tests, Traditional Diagnostic Tests, Molecular Diagnostic Tests); by Disease Indication (Tuberculosis, Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease, Others); by End User (Hospitals and Clinics, Diagnostics Laboratories, Others); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa).

Outlook 

• The respiratory diagnostics market is estimated to be at USD 8,011.21 Mn in 2024 and is anticipated to reach USD 10,472.33 Mn in 2029. 

• The respiratory diagnostics market is registering a CAGR of 5.5% during the forecast period of 2024-2029. 

• The respiratory diagnostics market is expanding rapidly due to the increasing prevalence of respiratory diseases and advancements in diagnostic technologies. The market is expected to grow steadily, driven by rising healthcare demand and government support.  

Request a free sample. 

Ecosystem 

• The participants in the global respiratory diagnostics industry are always developing their strategies to preserve a competitive advantage.  

• Rising demand for advanced diagnostics is driven by increasing respiratory diseases and technological advancements; new entrants focus on niche solutions and AI integration. 

• Several important entities in the respiratory diagnostics market include Koninklijke Philips N.V.; Becton, Dickinson and Co.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Bio-Rad Laboratories Inc.; and others. 

Ask for customization. 

Findings 

Attributes	Values
Historical Period	2018-2022
Base Year	2023
Forecast Period	2024-2029
Market Size (2024)	USD 8,011.21 Mn
Market Size (2029)	USD 10,472.33 Mn
Growth Rate	5.5% CAGR from 2024 to 2029
Key Segments	Product and Service (Instruments & Devices, Assays & Reagents, Software); Test Type (Mechanical Tests, Osa Diagnostic Tests, Imaging Tests, Traditional Diagnostic Tests, Molecular Diagnostic Tests); Disease Indication (Tuberculosis, Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease, Others); End User (Hospitals and Clinics, Diagnostics Laboratories, Others); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa)
Key Vendors	Koninklijke Philips N.V.; Becton, Dickinson and Co.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Bio-Rad Laboratories Inc.
Key Countries	The US; Canada; Mexico; Brazil; Argentina; Colombia; Chile; China; India; Japan; South Korea; The UK; Germany; Italy; France; Spain; Turkey; UAE; Saudi Arabia; Egypt; South Africa
Largest Market	North America

Get a free quote. 

Trends 

• AI-Powered Diagnostic Tools: The integration of AI in respiratory diagnostics is rapidly increasing. For example, the US FDA has approved several AI-powered tools for respiratory imaging, such as the algorithm developed by Zebra Medical Vision, which is used for early detection of lung diseases, showing a significant push toward AI adoption in healthcare. 

• Home-Based Diagnostic Kits: The COVID-19 pandemic has significantly nurtured the preference for home-based respiratory diagnostic kits. As consumers and healthcare systems adapted to the necessity of self-testing during the pandemic, Government health agencies, such as the CDC, continue to promote and fund self-testing, directing ongoing innovation and adoption in the market as respiratory disease challenges persist. 

• Advanced Biomarker Testing: Governments are funding biomarker research significantly, such as the NIH’s investment in precision medicine, including advanced biomarker testing for respiratory diseases. These initiatives aim to improve the accuracy of diagnostics and personalized treatment plans, reflecting a broader trend in the adoption of these technologies. 

Speak to analyst. 

Catalysts 

• Rising Prevalence of Respiratory Diseases: Respiratory diseases, such as asthma, affecting over 339 million people, continue to rise, increasing the demand for effective diagnostic tools. This factor highlights the urgent need for early and accurate diagnosis when managing these widespread conditions. 

• Technological Advancements: Innovations in diagnostics, including next-gen sequencing and molecular diagnostics, are revolutionizing the field by offering more precise and rapid results. These advancements are driving steady growth in the market, significantly enhancing the capabilities of respiratory diagnostics in detecting complex conditions. 

• Government Initiatives and Funding: Governments are significantly boosting healthcare infrastructure, with the U.S. alone allocating USD 7.6 billion for respiratory disease research in 2023. This funding supports the development of new diagnostic technologies and improves access to care, driving market growth globally. 

Inquire before buying. 

Restraints 

• High Costs of Advanced Diagnostics: The high cost of advanced respiratory diagnostic tools, with some tests exceeding USD 1,000, poses a barrier to widespread adoption, especially in low-income regions. 

• Regulatory Hurdles: Strict regulatory requirements can significantly extend the timeline for obtaining approval and bringing new diagnostic tools to market. These regulations, designed to ensure safety and efficacy, require thorough testing, documentation, and review, which can take an average of 18 to 24 months.  

• Limited Access in Developing Regions: Inadequate healthcare infrastructure in developing countries limits access to advanced respiratory diagnostics, with a significant portion of the population lacking access to essential diagnostic services. 

Personalize this research. 

Hotspot 

Explore purchase options. 

Table of Contents 

1.       Introduction         1.1.    Research Methodology         1.2.    Scope of the Study  2.       Market Overview / Executive Summary         2.1.    Global Respiratory Diagnostics Market (2018 – 2022)         2.2.    Global Respiratory Diagnostics Market (2023 – 2029)  3.       Market Segmentation         3.1.    Global Respiratory Diagnostics Market by Product and Service                3.1.1.    Instruments & Devices                3.1.2.    Assays & Reagents                3.1.3.    Software         3.2.    Global Respiratory Diagnostics Market by Test Type                3.2.1.    Mechanical Tests                3.2.2.    Osa Diagnostic Tests                3.2.3.    Imaging Tests                3.2.4.    Traditional Diagnostic Tests                3.2.5.    Molecular Diagnostic Tests         3.3.    Global Respiratory Diagnostics Market by Disease Indication                3.3.1.    Tuberculosis                3.3.2.    Asthma                3.3.3.    Lung Cancer                3.3.4.    Chronic Obstructive Pulmonary Disease                3.3.5.    Others         3.4.    Global Respiratory Diagnostics Market by End User                3.4.1.    Hospitals and Clinics                3.4.2.    Diagnostics Laboratories                3.4.3.    Others  4.       Regional Segmentation         4.1.    North America                4.1.1.    The US                4.1.2.    Canada                4.1.3.    Mexico         4.2.    South America                4.2.1.    Brazil                4.2.2.    Argentina                4.2.3.    Colombia                4.2.4.    Chile                4.2.5.    Rest of South America         4.3.    Asia Pacific                4.3.1.    China                4.3.2.    India                4.3.3.    Japan                4.3.4.    South Korea                4.3.5.    Rest of Asia Pacific         4.4.    Europe                4.4.1.    The UK                 4.4.2.    Germany                4.4.3.    Italy                4.4.4.    France                4.4.5.    Spain                4.4.6.    Rest of Europe         4.5.    The Middle East                4.5.1.    Turkey                4.5.2.    UAE                4.5.3.    Saudi Arabia                4.5.4.    Rest of the Middle East         4.6.    Africa                4.6.1.    Egypt                4.6.2.    South Africa                4.6.3.    Rest of Africa  5.       Value Chain Analysis of the Global Respiratory Diagnostics Market  6.       Porter Five Forces Analysis         6.1.    Threats of New Entrants         6.2.    Threats of Substitutes         6.3.    Bargaining Power of Buyers         6.4.    Bargaining Power of Suppliers         6.5.    Competition in the Industry  7.       Trends, Drivers and Challenges Analysis         7.1.    Market Trends         7.1.1.    Market Trend 1         7.1.2.    Market Trend 2         7.1.3.    Market Trend 3         7.2.    Market Drivers         7.2.1.    Market Driver 1         7.2.2.    Market Driver 2         7.2.3.    Market Driver 3         7.3.    Market Challenges         7.3.1.    Market Challenge 1         7.3.2.    Market Challenge 2         7.3.3.    Market Challenge 3  8.       Opportunities Analysis         8.1.    Market Opportunity 1         8.2.    Market Opportunity 2         8.3.    Market Opportunity 3  9.       Competitive Landscape         9.1.    Koninklijke Philips N. V.         9.2.    Becton, Dickinson and Co.         9.3.    Abbott Laboratories         9.4.    Thermo Fisher Scientific Inc.         9.5.    Bio-Rad Laboratories Inc.         9.6.    Company 6         9.7.    Company 7         9.8.    Company 8         9.9.    Company 9         9.10.  Company 10

Know the research methodology. 

Respiratory Diagnostics Market – FAQs 

1.  What is the current size of the respiratory diagnostics market? 

Ans. In 2024, the respiratory diagnostics market size is $8,011.21 Mn. 

2.  Who are the major vendors in the respiratory diagnostics market?  

Ans. The major vendors in the respiratory diagnostics market are Koninklijke Philips N.V; Becton, Dickinson and Co.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Bio-Rad Laboratories Inc. 

3.  Which segments are covered under the respiratory diagnostics market segments analysis?  

Ans. The respiratory diagnostics market report offers in-depth insights into Product and Service, Test Type, Disease Indication, End User, and Geography.